Last reviewed · How we verify
NA-831
NA-831 is a small molecule drug that targets the SGLT2 receptor.
NA-831 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | NA-831 |
|---|---|
| Also known as | NA-81 is a neuroprotective drug |
| Sponsor | Biomed Industries, Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
NA-831 works by inhibiting the SGLT2 receptor, which is involved in glucose reabsorption in the kidneys. This leads to increased glucose excretion in the urine, resulting in reduced blood glucose levels. By targeting this receptor, NA-831 aims to improve glycemic control in patients with diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
Key clinical trials
- NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection (PHASE2, PHASE3)
- A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19 (PHASE3)
- Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 (PHASE1)
- A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |